Cargando…

KRAS: Druggable at Last

The approval of adagrasib for non–small cell lung cancer is a milestone in drug development. This commentary highlights the history of the research that led to this breakthrough that will help many patients with KRAS-mutated cancers to live longer and better.

Detalles Bibliográficos
Autores principales: Herzberg, Benjamin O, Manji, Gulam A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078900/
https://www.ncbi.nlm.nih.gov/pubmed/36933199
http://dx.doi.org/10.1093/oncolo/oyad014

Ejemplares similares